Complete the form below to have a Genentech sales representative contact you with more information about Erivedge, including:
Data on file. Genentech, Inc.
Data on file. Genentech, Inc.
FDA approves Erivedge (vismodegib) capsule, the first medicine for adults with advanced basal cell carcinoma [press release]. San Francisco, CA: Genentech, Inc.; January 30, 2012.
FDA approves Erivedge (vismodegib) capsule, the first medicine for adults with advanced basal cell carcinoma [press release]. San Francisco, CA: Genentech, Inc.; January 30, 2012.
Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008;8(10):743-754.
Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008;8(10):743-754.
Scales SJ, de Sauvage FJ. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci. 2009;30(6):303-312.
Scales SJ, de Sauvage FJ. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci. 2009;30(6):303-312.
Erivedge® (vismodegib) capsule Prescribing Information. Genentech, Inc. March 2023.
Erivedge® (vismodegib) capsule Prescribing Information. Genentech, Inc. March 2023.
Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171-2179.
Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171-2179.
Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361(12):1164-1172.
Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361(12):1164-1172.
LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17(8):2502-2511.
LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17(8):2502-2511.
Gupta S, Takebe N, LoRusso P. Targeting the hedgehog pathway in cancer. Ther Adv Med Oncol. 2010;2(4):237-250.
Gupta S, Takebe N, LoRusso P. Targeting the hedgehog pathway in cancer. Ther Adv Med Oncol. 2010;2(4):237-250.
Cancer.org. How Targeted Therapies Are Used to Treat Cancer. https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/targeted-therapy/what-is.html. Accessed April 26, 2022.
Cancer.org. How Targeted Therapies Are Used to Treat Cancer. https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/targeted-therapy/what-is.html. Accessed April 26, 2022.
Lear JT, Corner C, Dziewulski P, et al. Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective. Br J Cancer. 2014;111(8):1476-1481.
Lear JT, Corner C, Dziewulski P, et al. Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective. Br J Cancer. 2014;111(8):1476-1481.
Ibrahim SF. Advanced basal cell carcinoma: treatment overview. The Dermatologist. 2014;22(3). https://www.hmpgloballearningnetwork.com/site/thederm/site/cathlab/event/advamced-basa-cell-carcinoma-treatment-overview. Published March 10, 2014. Accessed February 24, 2023.
Ibrahim SF. Advanced basal cell carcinoma: treatment overview. The Dermatologist. 2014;22(3). https://www.hmpgloballearningnetwork.com/site/thederm/site/cathlab/event/advamced-basa-cell-carcinoma-treatment-overview. Published March 10, 2014. Accessed February 24, 2023.
Levine A, Markowitz O. Update on advanced basal cell carcinoma diagnosis and treatment. Dermatology Times. https://www.dermatologytimes.com/view/update-advanced-basal-cell-carcinoma-diagnosis-and-treatment. Accessed March 29, 2023.
Levine A, Markowitz O. Update on advanced basal cell carcinoma diagnosis and treatment. Dermatology Times. https://www.dermatologytimes.com/view/update-advanced-basal-cell-carcinoma-diagnosis-and-treatment. Accessed March 29, 2023.
Amin SP, Russell KJ. Diagnosing, managing aBCC in elderly patients. Dermatology Times. https://www.dermatologytimes.com/view/diagnosing-managing-abcc-elderly-patients. Accessed March 29, 2023.
Amin SP, Russell KJ. Diagnosing, managing aBCC in elderly patients. Dermatology Times. https://www.dermatologytimes.com/view/diagnosing-managing-abcc-elderly-patients. Accessed March 29, 2023.
Erivedge® (vismodegib) capsule European Medicines Agency Assessment Report. September 15, 2016.
Erivedge® (vismodegib) capsule European Medicines Agency Assessment Report. September 15, 2016.
Lacouture ME, Dréno B, Ascierto PA, et al. Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma. Oncologist. 2016;21(10):1218-1229.
Lacouture ME, Dréno B, Ascierto PA, et al. Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma. Oncologist. 2016;21(10):1218-1229.
National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v3.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed August 26, 2022.
National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v3.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed August 26, 2022.
Solomon JA, Chever D, Iarrobino A, Caldwell C. Successful control of adverse events associated with vismodegib treatment of advanced basal cell carcinoma by recognition of hedgehog pathway activity in normal adult tissue. Poster presented at: International Investigative Dermatology Meeting; May 8-11, 2013; Edinburgh, Scotland, United Kingdom. Abstract 1088.
Solomon JA, Chever D, Iarrobino A, Caldwell C. Successful control of adverse events associated with vismodegib treatment of advanced basal cell carcinoma by recognition of hedgehog pathway activity in normal adult tissue. Poster presented at: International Investigative Dermatology Meeting; May 8-11, 2013; Edinburgh, Scotland, United Kingdom. Abstract 1088.
Sekulic A, Migden MR, Lewis K, et al. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015;72(6):1021-1026.
Sekulic A, Migden MR, Lewis K, et al. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015;72(6):1021-1026.
Fife K, Herd R, Lalondrelle S, et al. Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma. Future Oncol. 2017;13(2):175-184.
Fife K, Herd R, Lalondrelle S, et al. Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma. Future Oncol. 2017;13(2):175-184.
Ibrahim SF. Treating advanced basal cell carcinoma. https://www.the-dermatologist.com/content/treating-advanced-basal-cell-carcinoma. Accessed April 26, 2022.
Ibrahim SF. Treating advanced basal cell carcinoma. https://www.the-dermatologist.com/content/treating-advanced-basal-cell-carcinoma. Accessed April 26, 2022.
Le Moigne M, Saint-Jean M, Jirka A, et al. Dysgeusia and weight loss under treatment with vismodegib: benefit of nutritional management. Support Care Cancer. 2016;24(4):1689-1695.
Le Moigne M, Saint-Jean M, Jirka A, et al. Dysgeusia and weight loss under treatment with vismodegib: benefit of nutritional management. Support Care Cancer. 2016;24(4):1689-1695.
Sekulic A, Migden MR, Basset-Séguin N, et al; for the ERIVANCE BCC Investigators. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17(1):332. doi:10.1186/s12885-017-3286-5.
Sekulic A, Migden MR, Basset-Séguin N, et al; for the ERIVANCE BCC Investigators. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17(1):332. doi:10.1186/s12885-017-3286-5.
Mohan SV, Chang AL. Management of cutaneous and extracutaneous side effects of smoothened inhibitor therapy for advanced basal cell carcinoma. Clin Cancer Res. 2015;21(12):2677-2683.
Mohan SV, Chang AL. Management of cutaneous and extracutaneous side effects of smoothened inhibitor therapy for advanced basal cell carcinoma. Clin Cancer Res. 2015;21(12):2677-2683.
American Society of Clinical Oncology. Appetite Loss. https://www.cancer.net/coping-with-cancer/physical-emotional-and-social-effects-cancer/managing-physical-side-effects/appetite-loss. Accessed April 26, 2022.
American Society of Clinical Oncology. Appetite Loss. https://www.cancer.net/coping-with-cancer/physical-emotional-and-social-effects-cancer/managing-physical-side-effects/appetite-loss. Accessed April 26, 2022.
Basset-Séguin N, Hauschild A, Kunstfeld R, et al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017;86:334-348.
Basset-Séguin N, Hauschild A, Kunstfeld R, et al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017;86:334-348.
Ozgur OK, Yin V, Chou E, et al. Hedgehog pathway inhibition for locally advanced periocular basal cell carcinoma and basal cell nevus syndrome. Am J Ophthalmol. 2015;160(2):220-227.e2. doi:10.1016/j.ajo.2015.04.040
Ozgur OK, Yin V, Chou E, et al. Hedgehog pathway inhibition for locally advanced periocular basal cell carcinoma and basal cell nevus syndrome. Am J Ophthalmol. 2015;160(2):220-227.e2. doi:10.1016/j.ajo.2015.04.040
Clinicaltrials.gov. STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma. https://clinicaltrials.gov/ct2/show/NCT01367665. Accessed August 30, 2022.
Clinicaltrials.gov. STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma. https://clinicaltrials.gov/ct2/show/NCT01367665. Accessed August 30, 2022.
National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed August 30, 2022.
National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed August 30, 2022.
Erivedge® (vismodegib) capsule European Medicines Agency Assessment Report. September 15, 2016.
Erivedge® (vismodegib) capsule European Medicines Agency Assessment Report. September 15, 2016.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.